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Background: Few studies have attempted to characterise genomic changes occurring in hereditary epithelial ovarian carcinomas
(EOCs) and inconsistent results have been obtained. Given the relevance of DNA copy number alterations in ovarian oncogenesis
and growing clinical implications of the BRCA-gene status, we aimed to characterise the genomic profiles of hereditary and
sporadic ovarian tumours.
Methods: High-resolution array Comparative Genomic Hybridisation profiling of 53 familial (21 BRCA1, 6 BRCA2 and 26 non-
BRCA1/2) and 15 sporadic tumours in combination with supervised and unsupervised analysis was used to define common and/or
specific copy number features.
Results: Unsupervised hierarchical clustering did not stratify tumours according to their familial or sporadic condition or to their
BRCA1/2 mutation status. Common recurrent changes, spanning genes potentially fundamental for ovarian carcinogenesis,
regardless of BRCA mutations, and several candidate subtype-specific events were defined. Despite similarities, greater
contribution of losses was revealed to be a hallmark of BRCA1 and BRCA2 tumours.
Conclusion: Somatic alterations occurring in the development of familial EOCs do not differ substantially from the ones occurring
in sporadic carcinomas. However, some specific features like extensive genomic loss observed in BRCA1/2 tumours may be of
clinical relevance helping to identify BRCA-related patients likely to respond to PARP inhibitors.
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Epithelial ovarian cancer is the most lethal gynaecological
malignancy and the fifth leading cause of cancer-related death in
women in western countries. Due to lack of specific symptoms and
effective screening methods, the majority of cases are diagnosed at
advanced stages. Since survival probability drops significantly with
increasing stage, epithelial ovarian carcinoma (EOC) patients in
general face a poor prognosis, with an estimated 5-year survival
rate of around 27% (Siegel et al, 2012).
Epithelial ovarian cancer is a very heterogeneous disease that
can be stratified using different criteria. Based on molecular and
developmental features, EOCs can be divided into type I and
type II tumours. Type I tumours arise in a progressive manner
from benign, through borderline to low-malignant potential
neoplasm. Type II tumours grow rapidly without well-defined
premalignant lesions and are typically diagnosed as high-grade
serous, high-grade endometroid, or undifferentiated carcinomas
depending on the dominant pattern (Kurman and Shih Ie, 2011).
Tumours can also be classified as hereditary or sporadic when they
arise in patients with or without a family history of the disease,
respectively. Overall, around 10–15% of invasive EOCs are
estimated to involve hereditary susceptibility (Bast et al, 2009).
The majority of these cases are explained by germline mutations in
the BRCA1 or BRCA2 tumour suppressor genes (Bast et al, 2009;
Pennington and Swisher, 2012) although additional genes such as
BRIP1, RAD51C and RAD51D have been recently shown to confer
ovarian cancer susceptibility (Pennington and Swisher, 2012).
Clinical and histopathological differences between BRCA1- and
BRCA2-related tumours and those arising in non-mutation carriers
have been reported (Soslow et al, 2012). Importantly, germline
BRCA1/2 mutations have been associated with improved survival
and chemotherapy response (Alsop et al, 2012; Bolton et al, 2012;
Pennington and Swisher, 2012).
It has been suggested that hereditary and sporadic EOCs might
evolve in distinct ways, especially due to early homologous
recombination (HR) impairment in carriers of BRCA1 or BRCA2
mutations (Patael-Karasik et al, 2000; Israeli et al, 2003; Walsh
et al, 2008). However, it is still unclear exactly which mechanisms
are involved in cancer development in BRCA1/2 mutation carriers,
and whether they differ from those taking place in sporadic cases.
One way to get insight into this issue is to compare the rate and
pattern of DNA copy number changes exhibited by these tumour
types. This approach is particularly relevant in a view of the results
from the recently published Cancer Genome Atlas (TCGA) study
(TCGA, 2011). This the most comprehensive analysis of high-
grade EOCs carried out so far revealed that these tumours present
a relatively simple mutational spectrum, but are characterised by a
large degree of genome instability.
So far few studies have specifically analysed the DNA copy
number changes that characterise the different groups of hereditary
ovarian tumours (BRCA1, BRCA2 and those from non-BRCA1/
2-mutation carriers, also called ‘BRCAX’) or have compared these
changes with those observed in sporadic neoplasms (Patael-Karasik
et al, 2000; Zweemer et al, 2001; Israeli et al, 2003; Ramus et al,
2003; Leunen et al, 2009). Moreover, the few studies conducted
have yielded contradictory results, which might be due to the
limited number of tumours included (Patael-Karasik et al, 2000;
Israeli et al, 2003; Leunen et al, 2009), the use of low-resolution
techniques (Patael-Karasik et al, 2000; Ramus et al, 2003) or the
application of different algorithms. Interestingly, the TCGA
ovarian study reported that tumours with BRCA1/2 alterations
do not exhibit increased genomic instability compared with wild-
type tumours (TCGA, 2011). However, that comparison was only
made of the total level of DNA copy number alterations with no
distinction between gained or lost events. In addition, the TCGA
(TCGA, 2011) and other studies (Koul et al, 2000) jointly describe
the DNA copy number alterations that occur in tumours carrying
germline, somatic and/or epigenetic inactivation of the BRCA1 or
BRCA2 genes. Nevertheless, it is still not clear whether the
mechanisms by which these genes are rendered non-functional
might be relevant to the natural history of the tumours and to the
changes that arise and are selected throughout the oncogenic
process.
Our study addresses some of these limitations by using a
homogeneous series of ovarian tumours from patients of well-
characterised high-risk breast and ovarian cancer families. More-
over, this series includes not only cases from carriers of germline
BRCA1/2 mutations, but also from hereditary BRCAX cases. In
addition, we use high-resolution array Comparative Genomic
Hybridisation (aCGH) and pay special attention to the separate
analysis of gain and loss events. This approach, although still
limited, allowed us to obtain further insight into this poorly
explored field and to define potential differences and similarities in
genomic instability between these tumour groups.
MATERIALS AND METHODS
Additional information can be found in Supplementary Methods.
Patients and tumours. At total of 72 formalin-fixed paraffin-
embedded (FFPE) epithelial ovarian tumours were analysed. Fifty
seven corresponded to patients from high-risk breast and ovarian
cancer families and fifteen to sporadic patients. Families selected
for this study fulfilled one of the following criteria: (a) at least two
cases of ovarian cancer in the same family line; (b) at least one case
of ovarian cancer and at least one case of breast cancer in the same
family line; (c) at least one woman with both breast and ovarian
cancer; (d) at least one woman with bilateral ovarian cancer.
Mutation testing of BRCA1 and BRCA2 genes was carried out
using previously described methods (Milne et al, 2008). In total,
paraffin blocks from 21 BRCA1, 6 BRCA2 and 30 BRCAX tumours
were obtained from different hospitals throughout Spain. Sporadic
cases (with no reported first or second degree relative with breast
or ovarian cancer), used for comparison purposes, were obtained
from a single institution (Hospital Virgen del Rocio, Seville) and
were selected to match the distribution of histological subtypes in
familial series.
All tumours were blindly reviewed by two pathologists (IMR
and JP) and classified histopathologically. Immunohistochemical
expression of markers such as Wilms Tumour protein (WT1),
tumour protein p53 (TP53), oestrogen receptor (ESR), progester-
one receptor (PGR) and cyclin-dependent kinase inhibitor 2A
(p16) (CDKN2A) was performed to assist in the differential
diagnosis (Kobel et al, 2009; Kalloger et al, 2011). Grading of
serous tumours was performed according to two-tier MD
Anderson Cancer Center (MDACC) system (Malpica et al, 2004;
Gilks et al, 2008) while the rest of the histological types was graded
according to World Health Organisation criteria (Silverberg, 2000;
World Health Organization, 2004). A subgroup of tumours within
the type II carcinomas was defined to allow for comparisons
between more homogenous groups of high-grade neoplasms. This
subgroup consisted of high-grade serous tumours of solid growth
pattern and undifferentiated carcinomas (hereafter referred as to
‘subgroup of type II tumours’). Detailed information is shown in
Supplementary Table 1. The study was approved by the research
ethics committees from each of the participating centres and all
patients gave informed consent.
DNA isolation and labelling. Genomic DNA was extracted from
three 10-mm-thick FFPE tissue sections per tumour. After
deparaffination and rehydration, sections were hematoxylin and
eosin (H&E) stained and tumour areas were delimited by a
pathologist and macrodissected with a surgical blade to ensure at
least 80% tumour content. DNA extraction was carried according
to standard protocol including overnight proteinase K digestion
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and using QIAamp DNA mini kit (Qiagen, Westburg, Leusden,
The Netherlands) according to manufacturer’s instructions.
Labelling of test and reference DNA was performed with the Enzo
Genomic DNA labeling kit (Enzo Life Sciences, Farmingdale, NY,
USA) as described previously. In 45 out of 72 hybridisations (62%),
patient-matched normal DNA was used as a reference (in 26 from
conserved normal tissue and in 19 from the patient’s peripheral
blood). In the remaining 27 hybridizations (38%), a pool of normal
DNA from healthy females was used as a reference (http://
www.kreatech.com/products/megapool-reference-dna.html).
Hybridisations, scanning and image acquisition. Hybridisations
were performed on slides of four arrays, each containing 180 880
in situ synthesised 60-mer oligonucleotides (4 180K, Agilent
Technologies, Palo Alto, CA, USA) representing 169 793 unique
chromosomal locations evenly distributed across the genome
(spaceB17 kb), and 4548 additional unique oligonucleotides,
located at 238 of the Cancer Census genes (http://www.sanger.
ac.uk/genetics/CGP/Census/). Oligonucleotide positions were
defined according to the NCBI36/hg18 assembly (March 2006).
Hybridisation, scanning and feature extraction were carried out as
previously described (Buffart et al, 2008). The aCGH data have
been deposited in NCBI’s Gene Expression Omnibus (Edgar et al,
2002) and are accessible through GEO accession number
GSE41253 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE41253).
Preprocessing and processing. Data normalisation, segmen-
tation and calling were performed in R (v.2.8.2 and 2.13;
http://www.r-project.org), using median normalisation and Wave
Smoothing and CGH-call packages (van de Wiel and Zhang, 2007).
For visualisation and downstream processing, data were analysed
in Nexus Copy Number v5.1 (BioDiscovery, Inc., El Segundo, CA,
USA). The WECCA (Weighted Clustering of Called aCGH Data)
R package (Van Wieringen et al, 2008) was used for unsupervised
hierarchical clustering (total linkage and overall similarity
algorithms).
Degree of genomic instability: number and length of alterations.
To determine the degree of genomic instability in each subgroup of
tumours (BRCA1/2/X and sporadic), total number of alterations
and of a particular type (homozygous deletions (HDs)/losses/gains/
amplifications) were calculated per sample. Total size of altered
genome and size accounted for by gains and losses was calculated
by adding up the lengths of individual segments. Next, average
number of changes and average size of altered genome were
calculated for sporadic tumours and for each group of familial
tumours. To determine the relative contribution of each type of
change (losses or gains), the ratio of the average number of losses
to the average number of gains within each tumour subtype was
computed. Similarly, the ratio of the average length of the lost
genome to the average length of gained was calculated.
Common and potentially specific regions of copy number
changes. To visualise the general pattern of chromosomal
changes, frequency plots and a list of recurrent minimal common
regions (MCRs) of alterations were generated for each tumour
subtype (BRCA1/2/X and sporadic) using Nexus Copy Number
v5.1 (BioDiscovery, Inc.). Potentially group-specific alterations
were defined using Fisher’s Exact Test (FET) (P-valueo0.05)
implemented in Nexus and chi-square test within CGHtest
(R package) with correction for multiple testing (FDRo0.02).
The list of potentially group-specific regions was further refined
using data from the TCGA ovarian study (TCGA, 2011) as
described in Supplementary Materials.
Immunohistochemical analysis. To validate our hybridisation
and analytical approaches, we selected three high-amplitude events
(HDs at the CDKN2A and RB1 loci and amplification at the
CCNE1 locus) to determine the consistency between the assigned
DNA copy number status and the expression levels of the target
proteins. Details are explained in Supplementary Materials and
shown in Supplementary Table S2.
Statistical analyses. Statistical analyses were performed using
SPSS 17.0 (SPSS Inc., Chicago, IL, USA). Comparison of
continuous variables (number and size of alterations between
different tumour groups and clusters) was done using Student’s
two-tailed t-test (for variables of normal distribution) or the
Mann–Whitney test (non-parametric distributions). For catego-
rical data (FIGO stage, BRCA1/2 mutation status, etc.), chi-square
or Fisher’s Exact Test were applied, depending on the size of the
compared groups.
RESULTS
Tumour characteristics. In our series of 57 familial tumours, 4
were classified as borderline lesions and 53 corresponded to
carcinomas. The borderline tumours were analysed separately
(data not shown) and excluded from this study. All of them
belonged to the BRCAX group. Most tumours from BRCA1/2
mutation carriers were serous, high grade and high FIGO stage. In
contrast, BRCAX tumours were more heterogeneous and presented
a wider range of histological subtypes and stages. As expected,
hereditary patients were diagnosed at a significantly younger age
than sporadic ones (51 vs 62 years, P¼ 0.001). Patient and tumour
characteristics are summarised in Supplementary Table 1.
Number and length of copy number alteration across tumour
subtypes. Overall, the pattern of copy number alterations was not
substantially different between familial (all subtypes) and sporadic
tumours (Figure 1A). Likewise, there were no significant
differences between familial and sporadic tumours regarding the
average total number of alterations and the average total length of
genome altered per tumour (considering all carcinomas and the
subgroup of type II neoplasms, the latter defined as described in
Materials and methods) (Supplementary Table S3). Both familial
and sporadic tumours were characterised by a high level of
genomic instability, which in the subgroup of type II carcinomas
was exemplified by an average of460 aberrations per tumour that
involved41Mb of the genome (Supplementary Table S3). Despite
this general similarity, a separate analysis of gains and losses and
stratification of familial tumours according to their BRCA1/2
mutation status revealed some differences.
BRCA1 and BRCA2 tumours presented a greater average
number of losses and HDs than sporadic or BRCAX tumours,
while sporadic cases presented the highest average number of
gains and amplifications of all tumour subtypes (Figure 2A;
Supplementary Table S3). A similar pattern was observed when
only high-grade tumours were considered (Figure 2B;
Supplementary Table S3). Comparisons of gains and losses within
each tumour subtype revealed that sporadic tumours presented a
similar average number of both events (25.7 vs 25.6, respectively).
However, in familial tumours the average number of losses was 1.4
times greater than the average number of gains, with differences
mostly attributed to BRCA1 (29.6 losses vs 21.7 gains, P¼ 0.02)
and BRCA2 tumours (32.7 losses vs 14.5 gains, P¼ 0.009)
(Figure 2C; Supplementary Table S3). This was also observed in
the subgroup of type II tumours, with significant and borderline
significant differences between numbers of gains and losses in
BRCA2 and BRCA1 tumours, respectively (Figure 2D;
Supplementary Table S3).
In agreement with the analysis of the number of alterations, we
found that BRCA1 and BRCA2 tumours presented a significantly
higher average length of genome altered due to losses than sporadic
or BRCAX tumours (Figure 2E; Supplementary Table S3). This
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pattern was partially maintained in the subgroup of type II
carcinomas, with significant differences between tumours from
BRCA2 and BRCAX patients (Figure 2F; Supplementary Table S3).
Interestingly, in all tumour subtypes, including the sporadic group,
which showed similar average numbers of both alterations, more
genetic material was lost than gained (Figures 2G and H;
Supplementary Table S3). In BRCA1 and BRCA2 tumours, the
average length of lost genome was 2.1 and 3.8-fold greater than the
length of gained material, respectively. In sporadic and BRCAX
tumours, differences were less marked (1.6-fold in both)
(Figure 2G; Supplementary Table S3). Differences between length
of genome gained and lost per tumour were statistically significant
in all familial tumours (BRCA1, BRCA2 and BRCAX), while only a
trend was observed in sporadic cases (P¼ 0.09). In the subgroup of
type II tumours, only differences in BRCA1/2 carriers remained
significant (Po0.001) (Figure 2H; Supplementary Table S3).
Common and group-specific copy number alterations. A
summary of common gains and losses identified as recurrent in
at least three of the analysed tumour subtypes (BRCA1, BRCA2,
BRCAX and sporadic) is shown in Table 1. Regions recurrently
gained in the four tumour subtypes were 6p25.3, 8q24.2-q24.3 and
12p13.33-p13.32, and regions exhibiting the highest frequencies
were 3q26.2 and 8q24.2-q24.3 (Figure 1A–I; Table 1). These
regions and others defined as recurrently gained included from 1
up to 45 genes and spanned well-known or potential oncogenes
such as MECOM, PIK3CA, FOXQ1, MYC, CCND2 and CANT1.
Regions recurrently lost in all four subgroups were defined at
9p24.3, 9p21.3, 17q11.2-q12, 22q12.3, 22q13.1 and 22q13.31-
q13.33. Alterations of the highest incidence were found at 8p23.3-
p23.1 and 17p13.3-p11.2 (Figure 1A–I; Table 1). Many of these
deleted regions and the others qualifying as recurrent across
tumour subtypes encompassed tumour suppressors previously
linked to ovarian carcinogenesis (e.g.,MCPH1, CDKN2A, CDKN2B
and NF1). However, other regions pointed to less well-charac-
terised suppressors not previously associated with ovarian cancer
(e.g., FANCC, TSC1, CREBBP, CDH11 and EDA2R).
Despite the similar profile of copy number changes exhibited by
hereditary and sporadic tumours, supervised analysis unveiled
some regions potentially associated with particular tumour
subtypes (FDRo0.2) (Figure 1A; Supplementary Table S4).
Among the alterations more recurrently found in BRCA1 tumours
compared with sporadic cases were losses at 4q32.3-q34.1, 6q22.33-
q26 or 12q21.2-q23.2 (Figure 1A-IV) while gains at 6p12-p11,
10p14-p11 and 10q22 were found to be more frequent in BRCAX
tumours (compared with BRCA1 cases; Figure 1A-IV). Gains at
2p23.3, 12p11.22-p11.1 and 19q12-q13.11 were identified more
recurrently in sporadic cases (Figure 1A-II), with the latter
containing the CCNE1 gene that was also amplified in these
tumours.
High level amplifications and HDs. The high resolution of our
platform allowed us to identify focal high-amplitude copy number
changes. Fifty-nine narrow amplifications (median length of
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Figure 1. (A) Frequency plots of copy number gains (in green) and losses (in red) defined in all carcinomas and subgroups. The proportion of
tumours with gained/lost regions is plotted on the y axis versus genomic location on the x axis. Common recurrently altered regions across all four
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739Kb spanning on average 11 genes) were identified in at least
two cases (Supplementary Table S5, part A). For instance
amplification at 8q22.1, found only in BRCA1 tumours, presented
a MCR that spanned just one gene, the cancer-associated
LAPTM4B. The most frequent regions of amplification with their
distributions across the groups of tumours are shown in Table 2.
In addition, 57 focal HDs (median length of 465 Kbp spanning 6
genes on average) were identified in at least 2 samples (Table 2;
Supplementary Table S5, part B). The two most common HDs
(9% each) present in all tumour groups were found at 17q11.2 and
13q14.2; each deletion encompassed only one gene (NF1 and RB1,
respectively). Other frequent HDs common for sporadic and
familial tumours were defined at 8p23.2-p23.1, spanning the early
DNA damage-response gene MCPH1, and at the fragile site on
chromosome 3 (3p14.2) containing the known tumour suppressor
FHIT.
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Figure 2. Average number (A–D) and length (E–H) of copy number alterations in different groups of ovarian carcinomas (A, C, E, D) and a
subgroup of type II carcinomas (B, D, F, H). Significant differences in number and length of alterations between (A, B, E, F) and within (C, D, G, H)
tumour groups are indicated with *(Po0.05) or **(Po0.01). Error bars represent 95% Confidence Intervals. aSubgroup of type II carcinomas as
defined in Materials and methods.
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Table 1. Recurrent minimal common regions (MCRs) of gains and losses shared across tumour subtypes
Cytoband Region Size (bp)
Frequencya
(%)
No. of
genes Genes of interestb Other genes in the regionc
Gains
3q26.1 161 858 336–163 987 311 2128 975 37 6 ARL14 PPM1L B3GALNT1
NMD3 C3orf57 OTOL1
3q26.2 170 336 781–170 346 939 10158 56 1 MECOM
3q26.32 180277 629–180 352 072 74443 54 1 PIK3CA
5p14.3-p14.2 19 297 228–23 809 228 4512 000 28 5 CDH18 CDH12 PRDM9 CDH18 GUSBP1 PMCHL1
CDH12 PRDM9
6p25.3 1189 126–1 285 230 96104 38 1 FOXQ1
6p25.1-p24.3 5 776 997–8 041 186 2264 189 29 16 NRN1 TXNDC5
6p24.1 13 408 897–13 486 913 78016 32 2 TBC1D7 GFOD1
7q32.2-q32.3 129 620 363–130 651 373 1031 010 28 18
7q33-q34 134477 470–142 682 704 8205 234 30 80 CREB3L2 KIAA1549
BRAF
7q35-q36.1 144 378 243–147 685 879 3307 636 28 3 CNTNAP2 MIR548F4 MIR548T
8q24.21 128807 376–129 291 694 484318 68 2 MYC PVT1
8q24.3 141522 457–143 860 659 2338 202 65 21 TRAPPC9 PSCA
10q11.23 51473 718–51 664 989 191271 31 3 FAM21A FAM21B ASAH2
12p13.33-p13.32 54 933–5 102 331 5047 398 37 45 KDM5A CCND2
17q25.1-q25.3 70 225 044–72 286 125 2061 081 30 26 FOXJ1
17q25.3 74 387 898–78 774 742 4386 844 26 93 CANT1 ASPSCR1
20p13 0–3 018 638 3018 638 41 61 ANGPT4
Losses
4q24 103855 981–104 152 060 296079 51 4 MANBA UBE2D3 CISD2
NHEDC1
4q28.3-q31.21 136561 996–142 584 570 6022 574 46 19
4q34.3-q35.1 182 303 764–182 934 067 630303 49 1 NCRNA00290
6q26 161740 093–161 828 041 87948 44 1 PARK2
8p23.3-p23.1 1 190 650–6 260 759 5070 109 56 9 MCPH1
8p21.2-p21.1 26 260 243–28 304 348 2044 105 47 21
9p24.3 0–1 631 746 1631 746 51 11
9p24.1 8 056 737–8 434 111 377374 50 1 PTPRD
9p23-p22.3 12 386 932–14 108 018 1721 086 51 5 NFIB TYRP1 C9orf150 MPDZ
FLJ41200
9p22.3 14 622 555–16 229 616 1607 061 35 8
9p22.3-p21.3 16 479 078–20 933 035 4453 957 51 17 MLLT3
9p21.3 21969 065–22 051 061 81996 54 3 CDKN2A CDKN2B CDKN2BAS
9q21.33 88865 092–89 129 765 264673 44 2 LOC494127 C9orf170
9q22.32 96898 992–97 116 235 217243 43 1 FANCC
9q22.33-q31.1 100 644 626–101 678 237 1033 611 43 3 NR4A3 GALNT12 COL15A1 TGFBR1
ALG2 SEC61B
9q33.1 117 953 363–118 381 663 428300 46 3 PAPPA LOC100128505 ASTN2
9q33.2 123 060 025–123 208 621 148596 46 2 GSN STOM
9q33.3 128 975 869–129 006 542 30673 35 1 RALGPS1
9q34.13-q34.2 133 483 430–135 001 392 1517 962 51 17 TSC1
9q34.2 135 339 532–135 424 778 85246 53 2 TMEM8C ADAMTSL2
11p15.5-p15.4 826 091–2 876 898 2050 807 41 44
13q12.13 25719 218–25 817 850 98632 44 1 CDK8
16p13.3 3 759 661–3 782 779 23118 35 1 CREBBP
16q21 62541 693–64 974 691 2432 998 40 3 CDH11 LOC283867 CDH5
16q22.3-q23.1 73 046 913–74 862 172 1815 259 40 20
17p13.3 1 431 769–1 639 791 208022 57 11
17p11.2 19 082 703–20 046 930 964227 63 15
17q11.2-q12 26420 214–29 077 825 2657 611 54 4 NF1 TMEM98 SPACA3 ACCN1
18q21.2 48 644 312–51 715 504 3071 192 40 9
18q21.32-q21.33 55721 386–57 214 344 1492 958 40 2 PMAIP1 MC4R
18q23 75912 794–76 117 153 204359 44 3 ADNP2 LOC100130522
PARD6G
22q12.3 30 817 999–32 856 500 2038 501 43 12
22q12.3 32856 500–34 737 030 1880 530 53 10
22q12.3 34 737 030–35 049 039 312009 43 6 MYH9 RBFOX2 APOL3 APOL4 APOL2
APOL1
22q13.1 37668 125–37 724 138 56013 53 2 APOBEC3A APOBEC3B
22q13.1 43 530 191–46 673 931 3143 740 53 32
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Immunohistochemical validation of aCGH results. To validate
our aCGH results, we assessed the correlation between the assigned
DNA copy number and the immunohistochemical expression of
three genes targeted by high-amplitude events: CDKN2A and RB1
located at homozygously deleted regions, and CCNE1 that was
found amplified. Immunohistochemical analysis showed complete
lack or much lower expression of CDKN2A and RB1 in tumours
with HD at these loci compared with the mean value of samples
with a flat profile at 9p21.3 and 13q14.2, respectively
(Supplementary Figure S1A and B). Tumours exhibiting CCNE1
amplification presented much higher expression compared with
the mean value of tumours with normal DNA copy number at this
locus (Supplementary Figure S1C).
Unsupervised analysis. In addition to systematic comparison of
copy number alterations across different tumour subtypes, we also
carried out unsupervised analysis of the aCGH data to unveil
possible associations between particular patterns of genomic
changes and the sporadic or familial status of tumours (or
hereditary subtype, BRCA1/2/X). Unsupervised hierarchical clus-
tering stratified ovarian carcinomas (n¼ 68), based on their copy
number changes, into two main clusters (A and B) (Figure 1B, left
panel). Significant differences were not found between tumours
from both clusters (or from smaller subgroups) either according to
their general familial or sporadic condition or according to their
specific BRCA mutation status. In contrast, clustering was
associated with genomic instability level, FIGO stage and
histological subtype. The cluster with more genomically instable
tumours (cluster B) was significantly enriched in high FIGO stage
(P¼ 0.03) and serous type carcinomas (vs all other subtypes,
P¼ 0.001). Unsupervised hierarchical clustering of the subgroup of
type II tumours (n¼ 31) also rendered two clusters (II-A and II-B)
without significant enrichment in tumours from particular BRCA
subgroups (Figure 1B, right panel).
DISCUSSION
Few studies have addressed the characterisation of DNA copy
number changes arising in hereditary ovarian tumours, especially
in comparison with more extensively studied familial breast
tumours (Hedenfalk et al, 2003; Gronwald et al, 2005; Jonsson
et al, 2005; Mangia et al, 2008; Melchor et al, 2008; Joosse et al,
2009; Stefansson et al, 2009; Waddell et al, 2010; Didraga et al,
2011; Focken et al, 2011). The few existing studies have rendered
contradictory results, either supporting that mutations in BRCA1/2
affect the particular chromosomal alterations occurring throughout
cancer progression (Ramus et al, 2003, 2007), or reporting very few
copy number changes specifically associated to tumours harbour-
ing such mutations (Israeli et al, 2003; TCGA, 2011). Given these
antecedents, the recently confirmed relevance of copy number
changes as drivers of ovarian oncogenesis (TCGA, 2011) and the
growing clinical implications of the BRCA1/2 mutation status, we
aimed to determine how hereditary and sporadic ovarian tumours
relate to genomic instability and to define common and/or distinct
events occurring in the genesis and evolution of these neoplasms.
Different from most prior studies, we analysed tumours not only
from carriers of BRCA1/2 mutations, but also from non-BRCA1/2
hereditary patients (BRCAX tumours) as these have been
particularly poorly characterised. Also, we used a high-resolution
aCGH platform and separately analysed gains and losses (in
contrast to other studies correlating BRCA1/2 impairment only
with global instability).
Our findings indicate lack of substantial differences in the
pattern of DNA copy number changes displayed by sporadic
carcinomas and the different subtypes of familial tumours. This
similarity was illustrated by the existence of shared regions found
to be recurrently altered in each individual group of tumours.
These common events point to the involvement of genes
fundamental for ovarian carcinogenesis, selected throughout the
evolution of the tumours and providing advantage to any cancer
cell, independently of the existence of germinal mutations in the
BRCA1/2 genes. As possible candidates, we found known players
previously related to EOC such as PIK3CA, MECOM, MYC, NF1
and RB, but also less characterised genes, whose gains of function
(CDH12, FOXQ1, TXNDC5, CCND2, FOXJ1) and/or abrogation
(FANCC, TSC1, CREBBP, CDH11, EDA2R) might be crucial for
ovarian cancer development and/or progression. Exploration of the
therapeutic opportunities provided by these targets, to which a
majority of tumours are likely to be addicted, is an attractive
possibility. For instance, it has been suggested that modulation of
cellular activities of the forkhead transcription factor FOXQ1 may
have an application in cancer therapy since its inhibition blocks
epithelial to mesenchymal transition and results in cancer cell
sensitisation to a variety of chemotherapeutic agents (Qiao et al,
2011). Therapeutic approaches based on repression of cyclin D
gene have also been investigated (Tiedemann et al, 2008; Dong
et al, 2010) and may be applicable to EOCs presenting aberrant
CCND2 expression due to DNA-copy number gains. Likewise,
m-TORC1-directed therapies may be more effective in cancer
patients whose tumours present TSC1 (tuberous sclerosis
complex 1) genomic losses as it has been proposed for patients
whose tumour harbour TSC1 somatic mutations (Iyer et al, 2012).
Also exemplifying the absence of marked differences in the
profile of genomic changes of carriers and non-carriers of BRCA1/2
mutations, unsupervised hierarchical clustering did not stratify
tumours according to their familial or sporadic condition, nor did
it according to their BRCA1/2 mutation status. This is different
from what has been reported on familial BRCA1 and BRCA2 breast
tumours, which show association with particular molecular
subtypes (defined with expression arrays) and specific patterns of
copy number changes (Jonsson et al, 2005; Bergamaschi et al, 2006;
Table 1. ( Continued )
Cytoband Region Size (bp)
Frequencya
(%)
No. of
genes Genes of interestb Other genes in the regionc
22q13.31-q13.33 46673 931–49 472,215 2798 284 54 40
Xq11.1-q12 62673 834–65 512 219 2838 385 35 14
Xq12 65512 219–66 014 702 502483 46 1 EDA2R
Xq12-q13.1 66 014 702–68 066 344 2051 642 35 5 AR OPHN1 YIPF6 STARD8 EFNB1
Xq27.3 144 141 243–146 657 619 2516 376 41 21
Gained and lost regions listed as shared across tumour subtypes if present among the top 60 most frequently altered regions (minimum frequency¼ 25%) in at least three tumour subtypes
(BRCA1, B1; BRCA2, B2; BRCAX, BX; Sporadic, S). In bold regions found to be recurrent in all four tumour groups.
aGlobal frequency of the alteration in whole tumour set; frequencies greater or equal to 55% highlighted in bold.
bGenes of interest selected from Cancer Census (in bold) or based on their function and previously published data.
cRest of the genes in the defined region listed if less than seven.
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Table 2. Distribution of most frequent amplifications and homozygous deletions across tumour subtypes
No. of samples
with alteration
Cytoband Region
Size
(bp)
Frequencya
% All B1 B2 BX S
No. of
genes
Genes of
interestb
Other genes in
the regionc
Amplifications
3q26.2 170 112026–170 346939 234 913 5.9 4 1 3 1 MECOM MECOM
3q26.32-q26.33 179 526769–181 046005 1519 236 5.9 4 1 3 12 PIK3CA
7q36.3 155 939892–158 642803 2702 911 5.9 4 2 2 16
8q21.2-q21.3 85 047239–87 355110 2307 871 5.9 4 2 1 1 15
8q21.3 92 323386–92 443508 120 122 7.4 5 3 1 1 1 SLC26A7
8q22.1 94918806–95 029680 110874 5.9 4 3 1 1 PDP1
8q22.1 96 742090–97 658770 91 668 7.4 5 3 1 1 6 LOC100500773 GDF6
UQCRB
MTERFD1 PTDSS1 SDC2
8q22.1 98 814783–98 930489 115 706 8.8 6 6 1 LAPTM4B LAPTM4B
8q22.3 101 926982–102 101553 174 571 11.8 8 5 1 2 1 YWHAZ YWHAZ
8q23.1 107 121208–108 087190 965 982 10.3 7 4 3 2 OXR1 ABRA
8q23.1-q23.2 110 438342–111 177707 739 365 11.8 8 4 4 4 PKHD1L1 EBAG9 SYBU
KCNV1
8q24.11 118 543986–118 626272 82 286 14.7 10 3 1 6 1 MED30
8q24.13 122 701184–123 202812 501 628 13.2 9 3 1 5 2 HAS2 HAS2AS
8q24.21 128 537094–128 997964 460 870 19.1 13 5 2 6 2 MYC MYC PVT1
8q24.23-q24.3 139 929002–142 315091 2386 089 22.1 15 7 2 6 8 TRAPPC9 COL22A1 KCNK9 TRAPPC9
CHRAC1 EIF2C2 PTK2
DENND3 SLC45A4
11q13.1 64 958966–65 036226 77 260 11.8 8 3 2 3 2 MALAT1 MIR612 MALAT1
17q12-q21.1 35 083091–35 415740 332 649 5.9 4 2 2 11 ERBB2
19p13.2 8 939055–10 745326 1806 271 5.9 4 2 2 33 MUC16
20q13.2 51 530308–52 731992 1201 684 5.9 4 2 2 7 TSHZ2 ZNF217 SUMO1P1
BCAS1
CYP24A1 PFDN4 DOK5
20q13.31 54 436225–55 409396 973 171 5.9 4 1 2 1 12
Homozygous deletions
1p36.32 4 132552–4 616506 483 954 4.4 3 3 2 AJAP1 LOC284661 AJAP1
3p14.2 60 530653–60 943377 412 724 4.4 3 1 1 1 1 FHIT FHIT
5q15 95 249110–95 428565 179 455 4.4 3 1 1 1 1 ELL2
8p23.3 0–206 224 206 224 7.4 5 4 1 3 OR4F21 RPL23AP53
ZNF596
8p23.2-p23.1 6 177456–6 455595 278 139 7.4 5 3 1 1 2 MCPH1 MCPH1 ANGPT2
8p22-p21.3 17 000420–19 725139 2724 719 5.9 4 3 1 17 PCM1 MTUS1
8p21.3-p21.2 22 096663–26 106924 4010 261 7.4 5 4 1 37 DOCK5 CDCA2
EBF2
8p21.1-p12 28 636935–33 247321 4610 386 4.4 3 2 1 21 WRN DUSP4
HMBOX1 NRG1
13q14.2 47 841552–47 847231 5679 8.8 6 2 3 1 1 RB1 RB1
16q23.3 80 791319–82 209820 1418 501 4.4 3 3 2 CDH13 CDH13 MIR3182
17q11.2 26 516613–26 548438 31 825 8.8 6 1 1 2 2 1 NF1 NF1
19q13.43 61 855409–62 293274 437 865 4.4 3 1 1 1 6 PEG3 ZIM2 LOC147670 ZNF835 ZIM2
PEG3AS PEG3 MIMT1
22q13.31-
q13.33
46 034061–48 551789 2517 728 4.4 3 2 1 4 FLJ46257 MIR3201
FAM19A5 C22orf34
Xp22.11-p21.3 24 744413–25 039949 295 536 4.4 3 1 1 1 2 POLA1 ARX
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Melchor et al, 2008; Stefansson et al, 2009). Lack of segregation of
ovarian tumours from carriers and non-carriers of BRCA1/2
germline mutations based on their genomic instability pattern
would support a model according to which HR repair loss (through
inactivation of the BRCA1/2 genes or other members of the
pathway) would not only be a frequent event in high-grade serous
ovarian tumours, as recently demonstrated (TCGA, 2011), but also
an event occurring in the initial phases of tumour growth.
Interestingly, despite this general picture of similarity
between sporadic and hereditary tumours, differences concerning
the overall degree of genomic instability were revealed when
gains and losses were analysed separately. Copy number losses
were particularly abundant in BRCA1 and BRCA2 tumours, both in
global terms (comparison of losses made across tumour
subtypes) and relative to the number of gains (comparison within
each tumour subtype). Although greater contribution of
losses than gains was observed in all tumour subtypes, the extent
of this phenomenon was more prominent in carriers of
BRCA1 and BRCA2 mutations. Some prior studies, including the
most comprehensive one conducted by the TCGA Research
network in high-grade serous ovarian carcinomas, reported no
differences in the global degree of instability between tumours with
BRCA1/2 inactivating events and those with functional
BRCA1/2 genes (TCGA, 2011; Ramus et al, 2003). However, no
distinction was made between gains and losses, and only
comparison of total changes was conducted. Earlier studies
already suggested the relevance of loss of heterozygosity (LOH)
in ovarian tumours from BRCA1 and BRCA2 mutation carriers
(Walsh et al, 2008; Leunen et al, 2009; Wang et al, 2012), but
included very few familial cases (Walsh et al, 2008; Leunen et al,
2009) or used low-resolution platforms (Leunen et al, 2009). Our
results derived from analysis made across tumour types, within
each tumour subgroup and particularly when taking into account
only high-grade tumours highlight the relevance of genomic loss in
BRCA1 and BRCA2 tumours, a phenomenon that would not
merely reflect differences related to the higher grade or more
prevalent serous histotype of hereditary tumours. Interestingly,
correlation between extent of LOH and therapy sensitivity has been
recently reported in high-grade serous ovarian tumours (Wang
et al, 2012).
Our findings suggest that in the oncogenesis of ovarian
tumours, and in particular of hereditary BRCA1 and BRCA2
tumours, loss of function of tumour suppressor genes might
be under greater selection pressure than gain of function of
proto-oncogenes, at least through DNA copy number-related
mechanisms. However, lack of clear segregation of BRCA1 and
BRCA2 tumours in the unsupervised analysis would indicate that
most of the genomic loss in carriers does not involve a defined
group of critical regions (or specific suppressor genes) recurrently
selected during evolution of these particular tumours. Alterna-
tively, greater involvement of loss events in ovarian tumours might
be related to impairment of HR function, with grosser effects in
BRCA1 and BRCA2 tumours due to the central role played by both
genes within the pathway.
Although a consistent distinct pattern of copy number changes
does not seem to characterise BRCA1 and BRCA2 hereditary
ovarian tumours, we were able to define several individual regions
potentially associated with BRCA1 tumours (mainly losses) and a
few other aberrations (gains and amplifications) potentially
associated with sporadic tumours. For instance, losses defined at
4q32.1-q35.2, 13q13.3-q14.3, 17q11.1-q11.2, 17q12, 17q21.32-
q21.33, 17q24.3-q25.1 and 22q13.31 found to be related more
specifically to BRCA1 cases in our series, were also previously
reported to be associated with this tumour group (Zweemer et al,
2001; Ramus et al, 2003; Domanska et al, 2010). The ovarian
TCGA study reported only two regions being significantly enriched
in one tumour subtype, amplifications at 19p13.13 and 19q12
associated with sporadic tumours (vs BRCA-altered tumours).
Interestingly, gains and amplifications at 19q12 encompassing
CCNE1 were also defined as potentially associated with sporadic
tumours in our analysis. This finding reinforces the proposed role
for CCNE1 and of other proteins implicated in cell-cycle
progression as important contributors to ovarian carcinogenesis
in tumours with intact BRCA function (Bowtell, 2010; TCGA,
2011; Berns and Bowtell, 2012)
In summary, we have performed a comprehensive analysis of
the DNA-copy number changes that occur in hereditary EOCs. We
have found that overall hereditary and sporadic EOCs exhibit a
similar pattern of DNA copy number alterations. However, greater
contribution of losses was revealed to be a hallmark of BRCA1 and
BRCA2 mutation carriers. Importantly, this feature may help to
identify BRCA-related patients who have been shown to respond
to PARP inhibitors and to present better prognosis when treated
with standard regimes.
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